belumosudil
Orphan DrugFDA Approved
Description
Belumosudil is a selective ROCK2 inhibitor approved for chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy. It works by modulating immune cell trafficking and inflammatory responses. The drug represents a novel mechanism for managing refractory chronic GVHD.
Indications & Therapeutic Use
chronic graft-versus-host disease
Linked Diseases:
graft-versus-host disease
T86.0D006086
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
belumosudil
| Generic Name | belumosudil |
| Brands | 1 brand available |
| Active Ingredient | belumosudil mesylate |
| Drug Class | chronic graft-versus-host disease |
| Manufacturer | Kadmon Pharmaceuticals |
| Dosage Forms | Oral tablet, 200mg |
| Medical Code | L04AX09 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT03640481 |
| Countries | 2 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes